All In Biotech

Drug Trial Radar · NCT07609914

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

A PHASE 4, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF REDOSING OF RIMEGEPANT IN PARTICIPANTS 18 YEARS OF AGE OR OLDER FOR THE ACUTE TREATMENT OF MIGRAINE

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

May 28, 2026

Primary completion

Jun 7, 2028

Study completion Jun 7, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack. The primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.

Conditions

  • Acute Treatment of Migraine

Interventions

  • RimegepantDrug

    Rimegepant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs), serious TEAEs, and TEAEs leading to study intervention discontinuation on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overallTime frame: Up to 6 months
  2. Incidence of LFT elevations, AST >3x ULN, alanine aminotransferase ALT >3x ULN, and total bilirubin >2x ULN on treatment by average monthly redosing frequency over the entire OLT phase (<3, ≥3 to <6, ≥6 re-doses per month) and overallTime frame: Up to 6 months

Locations

38 sites in 3 countries. Site status is shown where the registry gives one.

  • Hope Clinical Research

    Canoga Park, California · Recruiting

  • Neuro-Pain Research Center

    Fresno, California · Recruiting

  • Clinical Research Institute

    Los Angeles, California · Recruiting

  • Neurology Offices of South Florida

    Boca Raton, Florida · Recruiting

  • AppleMedical Research Group, Inc.

    Miami, Florida · Recruiting

  • Brainstorm Research

    Miami, Florida · Recruiting

  • Clinical Neuroscience Solutions

    Orlando, Florida · Recruiting

  • Conquest Research-Winter Park

    Winter Park, Florida · Recruiting

  • Cedar Crosse Research Center

    Chicago, Illinois · Recruiting

  • Josephson Wallack Munshower Neurology

    Indianapolis, Indiana · Recruiting

  • Collective Medical Research

    Overland Park, Kansas · Recruiting

  • New England Regional Headache Center

    Worcester, Massachusetts · Recruiting

  • Michigan Headache & Neurological Institute

    Ann Arbor, Michigan · Recruiting

  • Minneapolis Clinic of Neurology - Burnsville Office

    Burnsville, Minnesota · Recruiting

  • Proven Endpoints, LLC

    Ridgeland, Mississippi · Recruiting

  • StudyMetrix Research

    City of Saint Peters, Missouri · Recruiting

  • Papillion Research Center / Avacare Clinical Research Network

    Papillion, Nebraska · Not yet recruiting

  • Alliance Clinical Research Las Vegas (Excel Clinical Research)

    Las Vegas, Nevada · Recruiting

  • M3 Wake Research - Las Vegas Rainbow

    Las Vegas, Nevada · Recruiting

  • Upstate Clinical Research Associates, LLC

    Williamsville, New York · Recruiting

  • Headache Wellness Center

    Greensboro, North Carolina · Recruiting

  • Abington Neurological Associates

    Abington, Pennsylvania · Not yet recruiting

  • FutureSearch Trials of Neurology

    Austin, Texas · Recruiting

  • FutureSearch Trials of Dallas

    Dallas, Texas · Recruiting

  • Red Star Research, LLC

    Lake Jackson, Texas · Recruiting

  • VIP Trials

    San Antonio, Texas · Not yet recruiting

  • Highland Clinical Research

    Salt Lake City, Utah · Not yet recruiting

  • Medstar Health - Department of Neurology

    McLean, Virginia · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Xianyang Hospital of Yan'an University

    Xianyang, Shaanxi, China · Not yet recruiting

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China · Not yet recruiting

  • Hillel Yaffe Medical Center

    Hadera, Israel · Recruiting

  • Sourasky Medical Center

    Tel Aviv, Israel · Recruiting

  • Rabin Medical Center

    Petah Tikva, Central District, Israel · Not yet recruiting

  • Sheba Medical Center

    Ramat Gan, Central District, Israel · Recruiting

  • Shaare Zedek Medical Center

    Jerusalem, Jerusalem, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.